Source: http://www.google.com/patents/US8088759?dq=5,915,131
Timestamp: 2017-04-28 10:57:37
Document Index: 687429146

Matched Legal Cases: ['Application No. 2006203946', 'Application No. 2', 'Application No. 05', 'Application No. 06', 'Application No. 08731682', 'Application No. 10', 'Application No. 09003224', 'Application No. 04', 'Application No. 05856659', 'Application No. 02794914', 'Application No. 00', 'Application No. 03', 'Application No. 04', 'Application No. 05']

Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2457405Sep 25, 1945Dec 28, 1948Monsanto ChemicalsHalo nitroparaffin modified aminoplastsUS3261828Oct 4, 1962Jul 19, 1966Hoffmann La Roche3h-1,4-benzodiazepine-2,5(1h,4h)-dione compoundsUS3374264Jul 27, 1965Mar 19, 1968Hoffmann La RocheN-haloacetyl-anthranilic acids and estersUS3384635Sep 28, 1966May 21, 1968Sterling Drug Inc1, 4-benzodiazepine derivativesUS3415814Mar 9, 1967Dec 10, 1968Sterling Drug Inc4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dioneUS3847905Oct 29, 1971Nov 12, 1974Knoll Ag1,5-benzodiazepine derivativesUS4076823Aug 18, 1977Feb 28, 1978E. R. Squibb & Sons, Inc.Triazolo-2,4-benzodiazepinesUS4088756Nov 28, 1975May 9, 1978The Regents Of The University Of MichiganPharmaceutical composition and process of treatmentUS4108852Feb 4, 1977Aug 22, 1978Knoll Ag.Process for preparing 1,5-benzodiazepine-2-onesUS4110337Mar 8, 1974Aug 29, 1978Lipha, Lyonnaise Industrielle PharmaceutiqueTriazolobenzodiazepinesUS4495101Apr 28, 1983Jan 22, 1985American Home Products CorporationAntiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivativesUS4551480Mar 2, 1984Nov 5, 1985Stiefel Laboratories, Inc.Compositions for the treatment of psoriasisUS4560684Dec 13, 1983Dec 24, 1985Shionogi & Co., Ltd.1,4-Benzodiazepine derivativesUS4623646Oct 1, 1985Nov 18, 1986Boehringer Ingelheim KgPAF-antagonistic diazepines, methods of useUS4751223Oct 14, 1986Jun 14, 1988Hoechst-Roussel Pharmaceuticals, Inc.Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepinesUS4820834Mar 16, 1987Apr 11, 1989Merck & Co., Inc.Benzodiazepine analogsUS4894366Nov 20, 1985Jan 16, 1990Fujisawa Pharmaceutical Company, Ltd.Tricyclo compounds, a process for their production and a pharmaceutical composition containing the sameUS4898861Aug 29, 1988Feb 6, 1990Hoffmann-La Roche Inc.Method for inhibiting the proliferation of tumor cellsUS4916138Jul 25, 1988Apr 10, 1990Fujisawa Pharmaceutical Co., Ltd.Solid dispersion composition of FR-900506 substanceUS4929611May 30, 1986May 29, 1990Fujisawa Pharmaceutical Company, Ltd.Method for immunosuppressionUS4946778Jan 19, 1989Aug 7, 1990Genex CorporationSingle polypeptide chain binding moleculesUS5004741Nov 9, 1988Apr 2, 1991Merck & Co., Inc.Methods of antagonizing CCK or gastrin with benzodiazepine analogsUS5041438Oct 30, 1989Aug 20, 1991Hoffmann-La Roche Inc.Method for treating retroviral infections with benzodiazepine compoundsUS5141930Jul 8, 1991Aug 25, 1992Yoshitomi Pharmaceutical Industries, Ltd.Fused thiophene compounds and uses thereofUS5147872Jun 19, 1990Sep 15, 1992Golwyn Daniel HTreatment of immunologically based disorders, specifically psoriasisUS5216148Feb 27, 1992Jun 1, 1993Hoffmann-La Roche Inc.Carboxamides and anilidesUS5288514Sep 14, 1992Feb 22, 1994The Regents Of The University Of CaliforniaSolid phase and combinatorial synthesis of benzodiazepine compounds on a solid supportUS5324726Oct 29, 1992Jun 28, 1994Merck & Co., Inc.Benzodiazepine analogsUS5391566Jul 20, 1993Feb 21, 1995Merck & Co., Inc.Benzimidazolinones substituted with phenoxyphenylacetic acid derivativesUS5444092Jul 20, 1994Aug 22, 1995Collins; JerryMethod and composition for treating psoriasisUS5521170Mar 31, 1994May 28, 1996Fujisawa Pharmaceutical Co., Ltd.Benzamide derivatives and pharmaceutical composition comprising the sameUS5545568Dec 2, 1993Aug 13, 1996The Regents Of The University Of CaliforniaSolid phase and combinatorial synthesis of compounds on a solid supportUS5559230Jun 10, 1993Sep 24, 1996Otsuka Pharmaceutical Co., Ltd.Benzoheterocyclic compoundsUS5591227Apr 27, 1995Jan 7, 1997Medtronic, Inc.Drug eluting stentUS5597915Mar 15, 1993Jan 28, 1997Merck Sharp & Dohme Ltd.Benzodiazepine derivatives, compositions containing them and their use in therapyUS5599352Sep 15, 1994Feb 4, 1997Medtronic, Inc.Method of making a drug eluting stentUS5633251Aug 17, 1995May 27, 1997Merck & Co., Inc.N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepinesUS5677282Jun 7, 1995Oct 14, 1997Proscript, Inc.Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinaseUS5697967Apr 27, 1995Dec 16, 1997Medtronic, Inc.Drug eluting stentUS5763437Jul 27, 1995Jun 9, 1998Fujisawa Pharmaceutical Co., Ltd.Benzodiazepine derivativesUS5776946Aug 28, 1995Jul 7, 1998Mcgeer; Patrick L.Peripheral benzodiazepine receptor ligands as antiinflammatory agentsUS5861380Dec 6, 1996Jan 19, 1999Cortech, Inc.Serine protease inhibitors-keto and di-keto containing ring systemsUS5962337Dec 23, 1997Oct 5, 1999Pharmacopeia, Inc.Combinatorial 1,4-benzodiazepin-2,5-dione libraryUS6004942Aug 30, 1996Dec 21, 1999The Regents Of The University Of CaliforniaMethods for treating arthritis by administering an apoptosis regulatorUS6074859Jul 8, 1998Jun 13, 2000Kikkoman CorporationMutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent proteinUS6080568Aug 19, 1997Jun 27, 2000Genencor International, Inc.Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformisUS6100254Oct 10, 1997Aug 8, 2000Board Of Regents, The University Of Texas SystemInhibitors of protein tyrosine kinasesUS6239131Dec 10, 1997May 29, 2001Zeria Pharmaceutical Co., Ltd.1,5 Benzodiazepine derivativesUS6277844Sep 14, 1999Aug 21, 2001Sydney SpectorCompound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosisUS6319931Jun 14, 1999Nov 20, 2001Centre National De Al Recherche Scientifique (Cnrs)Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapyUS6506744Jul 7, 2000Jan 14, 2003Hoffmann-La Roche Inc.Benzazepinone-derivativesUS6524623Aug 7, 2000Feb 25, 2003Milton HodoshTherapeutic compositions and methods of use thereofUS6524832Sep 19, 1994Feb 25, 2003Arch Development CorporationDNA damaging agents in combination with tyrosine kinase inhibitorsUS6579854May 6, 1998Jun 17, 2003Vanderbilt UniversityDiagnosis and management of infection caused by chlamydiaUS6605593Aug 14, 2000Aug 12, 2003Isotechnika, Inc.Deuterated cyclosporine analogs and their use as immunomodulating agentsUS6613739Aug 7, 2000Sep 2, 2003Isotechnika, Inc.Deuterated cyclosporine analogs and their use as immunomodulating agentsUS6767533Nov 10, 1999Jul 27, 2004Sanofi-SynthelaboUse of a substance binding with the peripheral benzodiazepin receptor for treating skin stressUS6824561Dec 20, 2000Nov 30, 2004Medtronic, Inc.Implantable system with drug-eluting cells for on-demand local drug deliveryUS6916813Dec 10, 2002Jul 12, 2005Bristol-Myers Squibb Co.(1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolaseUS7125866Apr 27, 2000Oct 24, 2006Regents Of The University Of MichiganTherapeutic applications of pro-apoptotic benzodiazepinesUS7144880May 1, 2003Dec 5, 2006Regents Of The University Of MichiganCompositions relating to novel compounds and targets thereofUS7150433Aug 15, 2003Dec 19, 2006Toyota Motor Sales, U.S.A., Inc.Aircraft bolster traysUS7175953Jul 25, 2003Feb 13, 2007Institute Fuer Diagnostik ForschungShort-warp peptide-dye conjugate as contrast agent for optical diagnosticUS7220739Jan 22, 2001May 22, 2007Regents Of The University Of MichiganTherapeutic application of pro-apoptotic benzodiazepinesUS7250410Jun 7, 2002Jul 31, 2007Via Pharmaceuticals, Inc.Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereofUS7276348Mar 8, 2004Oct 2, 2007Regents Of The University Of MichiganCompositions and methods relating to F1F0-ATPase inhibitors and targets thereofUS7351241Jul 23, 2003Apr 1, 2008Carl Zeiss Meditec AgMethod and apparatus for precision working of materialUS7572788May 1, 2003Aug 11, 2009The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofUS7638624Jan 3, 2006Dec 29, 2009The Regents Of The University Of MichiganCompositions and methods relating to novel benzodiazepine compounds and derivativesUS7683046Apr 28, 2008Mar 23, 2010The Regents Of The University Of MichiganBenzodiazepine compositions for treating epidermal hyperplasia and related disordersUS7851465Mar 7, 2008Dec 14, 2010The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofUS20020025946Apr 26, 2001Feb 28, 2002Buchanan Charles M.Acylated cyclodextrin: guest molecule inclusion complexesUS20020048566Sep 13, 2001Apr 25, 2002El-Deiry Wafik S.Modulation of cellular apoptosis and methods for treating cancerUS20020128208Dec 17, 2001Sep 12, 2002Snyder James P.Nonpeptide agonists and antagonists of vasopressin receptorsUS20030044776Sep 25, 1998Mar 6, 2003James A. DykensCompositions and methods for identifying agents that alter mitochondrial permeability transition poresUS20030119029Aug 13, 2002Jun 26, 2003Regents Of The University Of MichiganCompositions and methods relating to novel benzodiazepine compounds and targets thereofUS20040009972Jun 13, 2003Jan 15, 2004Ding Charles Z.Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolaseUS20040087489Sep 11, 2003May 6, 2004Antonio RuizCompositions and methods for the treatment of mycobacterial infectionsUS20040157833Dec 3, 2003Aug 12, 2004Vela Pharmaceuticals, Inc.Pharmaceutical composition of 1- (3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereofUS20040176358Aug 4, 2003Sep 9, 2004The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofUS20050113460Sep 7, 2004May 26, 2005The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofUS20050261176May 1, 2003Nov 24, 2005The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofUS20050272723Apr 20, 2005Dec 8, 2005The Regents Of The University Of MichiganMethods and compositions for treating diseases and conditions associated with mitochondrial functionUS20060025388Jul 7, 2004Feb 2, 2006Glick Gary DCompositions and methods relating to novel compounds and targets thereofUS20060052369Jul 6, 2005Mar 9, 2006The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofUS20060166975Jan 3, 2006Jul 27, 2006Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofUS20070036854Oct 23, 2006Feb 15, 2007Glick Gary DTherapeutic applications of pro-apoptotic benzodiazepinesUS20070043033Jun 1, 2006Feb 22, 2007The Regents Of The University Of MichiganUnsolvated benzodiazepine compositions and methodsUS20070105844Oct 25, 2006May 10, 2007Regents Of The University Of MichiganTherapeutic compositions and methodsUS20070111994Nov 1, 2006May 17, 2007Regents Of The University Of MichiganNovel 1,4-benzodiazepine-2,5-diones with therapeutic propertiesUS20070135418Dec 21, 2006Jun 14, 2007Glick Gary DCompositions and methods relating to novel compounds and targets thereofUS20070299059May 25, 2007Dec 27, 2007Glick Gary DCompostions and methods relating to novel compounds and targets thereofUS20080064686Apr 26, 2007Mar 13, 2008The Regents Of The University Of MichiganNovel soluble 1,4 benzodiazepine compounds and stable salts thereofUSRE30293Apr 19, 1979Jun 3, 1980Knoll A.G.Process for preparing 1,5-benzodiazepine-2-onesCA2372150A1Apr 27, 2000Nov 9, 2000The Regents Of The University Of MichiganTherapeutic applications of pro-apoptotic benzodiazepinesCA2457405A1Aug 15, 2002Feb 27, 2003The Regents Of The University Of MichiganCompositions and methods relating to benzodiazepine compoundsDE1810423A1Nov 22, 1968Oct 9, 1969Boehringer Sohn Ingelheim1-Phenyl-4-alkyl-3H-1,4-benzodiazepin-2,5-[1H,4H]-dione und Verfahren zu ihrer HerstellungEP0227539A1Dec 11, 1986Jul 1, 1987Roussel-Uclaf4H-triazolo [4,3-a][1,4] benzodiazepines, process for their preparation, their use as medicaments and compositions containing themEP0349949A2Jul 1, 1989Jan 10, 1990Fujisawa Pharmaceutical Co., Ltd.Benzodiazepine derivativesEP0906907B1Sep 20, 1996Mar 6, 2002Institute of Medicinal Molecular Design, Inc.Compounds potentiating retinoidEP1143946B1Apr 27, 2000Jan 28, 2004The Regents Of The University Of MichiganUse of benzodiazepines for treating autoimmune diseases induced by apoptosisEP1398033B1Apr 27, 2000Jun 17, 2009The Regents Of The University Of MichiganUse of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosisEP1423122A2Aug 15, 2002Jun 2, 2004The Regents Of The University Of MichiganCompositions and methods relating to novel benzodiazepine compounds and targets thereofEP1622684A2Apr 30, 2004Feb 8, 2006The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofEP1742460A1Jun 18, 2005Jan 10, 2007TTE Germany GmbHRaster distortion correction circuitEP1778204A2Jul 7, 2005May 2, 2007The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and traget thereofEP1786429A2Sep 7, 2005May 23, 2007The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofEP1845996A1Jan 3, 2006Oct 24, 2007The Regents Of The University Of MichiganCompositions and methods relating to novel compounds and targets thereofGB1363735A Title not availableRU2096044C1 Title not availableWO2000066106A2 *Apr 27, 2000Nov 9, 2000The Regents Of The University Of MichiganUse of benzodiazepines for treating autoimmune diseases induced by apoptosis* Cited by examinerNon-Patent CitationsReference1Abunasser, et al., "Etanercept-Induced Lupus Erythematosus Presenting as a Unilateral Pleural Effusion," Chest 2008, 134: 850-853.2Adachi, M., et al., "Aberrant Transcription Caused by the Insertion an Early Transposable Element . . . ," PNAS. USA-90:1756-1760 (1993).3Adelman, N. E., et al., Treatment of (NZB X NZW)F1 Disease with Anti-I-A Monoclonal Antibodies; J. Exp. Med.-158:1350.1355 (1983).4Akssira, M., et al., "New Routes to 1,4-benzodiazepin-2,5-diones," Tetrahedron (1994), vol. 50, No. 30, pp. 9051-9060.5Algarra, et al., "Application of the Photo-Fries Rearrangement of Aryl N-Chloroacetylanthranylates as Key Step in the . . . ", Heterocycles, vol. 36 1993, pp. 2335-2344.6Appleby, et al., "Murine chronic graft-versus-host disease as a model of osystemic lupus erythematosus: effect of immunosuppressive drugs on disease development," Clin. Exp. Immunol. (1989) 78, 449-453.7Atwal et al., Tet Lett. 30, 1989, 7313.8Atwal, K.S., et al., "N-(1-Aryl-2-(1-imidazolo)ethyl)-guanidine derivates as potent inhibitors of the bovine mitochondrial F140 ATP hydrolase" Bioorganic & Medicinal Chem. Ltr., vol. 14, pp. 1021-1030 (2004).9Atwal, K.S., et al., "Small Molecule Mitochondrial F1F0 ATPase Huydrolase Inhibitors as Cardioprotective Agents" J. Med. Chem. 47, pp. 1081-1084 (2004).10AU Examiners Report, AU Patent App. No. 2005323519 dated Nov. 27, 2007.11AU Patent Application No. 2006203946 Examiner's Report dated Sep. 10, 2008.12Baader, S.L., et al., Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid . . . Anticancer Research-14:221-228 (1994).13Bastian, et al., "Casein Interference in Bovine Plasmin Assays Using a Synthetic Substrate," (1991) J Dairy Sci 74:4119-4124.14Beale, P.J., et al., "BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma," British Journal of Cancer—82 (2) :436-440 (2000).15Beurdeley-Thomas, et al., "The peripheral benzodiazepine receptors: a review," Journal of Neuro-Oncology 46 (2000) 45-56.16Bhagavathula, Narasimharao, et al., "7-Chloro-t-(4-hydroxyphenyl—-1-methyl-3-(naphthalen-2-ylmethyl) . . . ", J. Pharmacol & Exp Ther 324: 938-947 (2008).17Bisaha, S.N., et al., A switch in enantiomer preference between mitochondrial F1F0-ATPase chemotypes, Bioorganic & Medicinal Chemistry Letters, 2005 15(11), pp. 2749-2751.18Blatt, Neal B., "Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility", The Journal of Clinical Investigation, Oct. 2002, vol. 110, No. 8., pp. 1123-1132.19Blum, P., et al., "Stiff-Person Syndrome: An Autoimmune Disease," Movement Disorders 6(1):12-20 (1991).20Boitano, Anthony, et al., "Structure activity studies of a novel cytotoxic benzodiazepine", Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 13, No. 19, 2003, pp. 3327-3330.21Bolli, M.H., et al., "Novel Benzo[1,4]diazepin-2-one-Derivaties as Endothelin Receptor Antagonists", Journal of Medicinal Chemistry, vol. 47, No. 11, Apr. 23, 2004, pp. 2776-2795.22Bonnot, O., et al., (2003) Encephale. 29(6):553-559.23Bono et al., "Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities," Biochemical and Biophysical Research Communications, 1999, 265, pp. 457-461.24Boojamra, C.G., et al., "Solid-Phase Synthesis of 1,4.Benzodiazepine-2,5-Diones. Library Prep. and Demonstration of Synthesis Generality," J. Org. Chem.-62:1240-1256 (1997).25Boojamra, Constantine G., et al., "An Expedient and High-Yielding Method for the Solid-Phase Synthesis of Diverse 1,4-Benzodiazepine-2, 5-diones," Journal of Organic Chemistry, 1995, vol. 60, No. 18, pp. 5742-5743.26Borea, "Stereochemical Features Controlling Binding and Intrinsic Activity Properties of Benzodiazepine Receptor Ligands", Molecular Pharmacology, Apr. 1987, 31 (4), pp. 334-344, p. 344, Abstract.27Bossu, et al., "IL-18 cDNA vaccination protects mice from spontaneous lupus-like automimmune disease," PNAS 2003, 100: 14181-14186.28Buffett-Jerrott S.E. et al. (2002) Curr. Pharm. Des. 8(1):45-58.29Bunin et al., "Synthesis and evaluation of 1,4-benzodiazepine libraries", Methods in Enzymology, 1996, 267, pp. 448-465.30Bunin, B.A., et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Libra ," PNAS USA-91:4708-4712 (1994).31Bunin, BA., et al., "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodlazepine Derivatives," J. Am. Chem. Soc.—114:10997-10998 (1992).32Busca, et al., "Recombinant human soluble tumor necrosis factor recptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplatation," Am. J. Hematol., 2007, 82: 45-52.33Canadian Patent Search, CA Patent Application No. 2,457,405, dated Feb. 6, 2007.34Casedo, M., et al. (2002) J. Exp. Med. 196(9):1121-1125.35Chumakov,A.M., et al., "Analysis of p53 Transactivation Through High-Affinity Bindir•g Sites," Oncogene-8:3005o3011 (1993).36Churcher et al., "A new series of potent benzodiazepine γ-Secretase inhibitors," Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-.37Cohen, P.L., et al., "Lpr and gld: Single Gen• Models of Systemic Autoimmunity and Lymphoproliferative Disease," Annu. Rev. Immunol. 9:243-269 (1991).38Cole et al., "The EBV-Hybridoma Technique and its Application to Human Lung Cancer", Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 [1985].39Colosi, et al,"Mutational analysis of the intracellular domain of the human growth hormone recetor", J. Biol. Chem., 268:12617 [1993].40Covelli, Vito, "Stress, Neuropsychiatric Disorders and Immunological Effects Exerted by Benzodiazepines," Immunopharmacology and Immunotoxicology, 20(2), 199-209 (1998).41Crabtree, R.H., "A New Type of Hydrogen Bond," Science 282:2000-2001 1998.42Cunha, 2002, "Bismuth nitrate pentahydrate: a new and environmentally benign reagent for guanidylation of N-benzoylthioureas", Tetrahedron Letters 43: 49-52.43Cunha, 2006, "The first bismuth(III)-catalyzed guanylation of thioureas", Tetrahedron Letters 47:6955-56.44Dacaudin, D. (2004) 15(8):737-745.45Darrow et al., "Structurally similar small molecule photoaffinity CCK-A Agonists and Antagonists as Novel Tools . . . ", Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132.46De Bandt, et al., "Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey," Arthritis Res. & Ther., 2005, 7: R545-R551.47Desjardins, P and Stephanie Ledoux, "The Role of Apoptosis in Neurodegenerative Disease," Metabolic Brian Disease, vol. 13, No. 2, pp. 79-96 (1998).48Desoize, B., "Anticancer Drug Resistance and Inhibition of Apoptosis," Anicancer Research—14:2291-2294 1994.49Dichek, David A., et al., "Seeding of intravascular stents with genetically engineered endothelial cells," Laboratory Investigation, 80:5 pp. 1347-1353 (1989).50Doble, A., et al., "Labelling of Peripheral-Type Benzodiazepine B Human Brain with [aH]l 1195: Anatomical and Subcellular Distribution," Brain Research Bulletin,18:49-61 1987.51Don, A. et al., Cancer Cell, vol. 3, May(2003) 497-509.52Donadio, J.V., et al., 'Immunosuppressive Drug Therapy in Lupus Nephritis, American Journal of Kidney Diseases 21 (3):239-250 1993.53Dourlat, et al., "Novel 1,4-benzodiazepine derivaties with antiproliferative properties on tumor cell lines," Bioorganic & Medicinal Chemistry Letters, 2007, vol. 17, Issue 9, pp. 2527-2530.54Elz et al., 1989 Eur. J. Med Chem. 259-262.55EP Patent Application No. 05 80 4417 Supplementary European Search Report dated Mar. 26, 2009.56EP Patent Application No. 06 717616 Supplementary Search Report dated Mar. 26, 2009.57EP Search Report dated Aug. 10, 2010, EP Patent Application No. 08731682.4.58EP Search Report dated Jun. 23, 2010, EP Patent Application No. 10 003 823.1.59EP Search Report dated Nov. 26, 2009, EP Patent Application No. 09003224.4.60EP Search, EP Patent App. No. 03 027 484.9-2117, dated Jan. 31, 2005.61EP Search, EP Patent Application No. 04 775 923.8, dated Dec. 15, 2008.62EP Search, EP Patent Application No. 05856659, mailed Dec. 9, 2008.63EP Supplementary Search Report, EP Application No. 02794914.8 dated Nov. 6, 2008.64Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," Laboratory Investigation 61(4):447-456 1989.65European Search Report, EP Patent Application No. 00 928 586.7-2117 dated Apr. 23, 2002.66European Search Report, EP Patent Application No. 03 027 484.9-2117 dated May 3, 2004.67European Search Report, EP Patent Application No. 04 775 923.8-2123 dated Nov. 9, 2007.68European Search Report, EP Patent Application No. 05 769 345.9 dated Oct. 22, 2007.69Francis, T.M., et al., "Identification of cytotoxic, T-cell-selective 1,4-benzodiazepine-2,5-diones," Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, GB, vol. 16, No. 9, May 1, 2006, pp. 2423-2427.70Fry, L (1988), Brit. J. Dermatol., 119:445-461.71Fuh et al, "Rational design of potent antagonists to the human growth hormone receptor", Science, 256:1677 [1992].72Galiegue, S., et al. (2003) Curr. Med. Chem (10(16):1563-1572.73Gallant, J.E., et al.,"Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human . . . " The Journal of Infect. Disease, 166: 1223-122 (1992).74Garcia-Calvo, M., et al. "Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors," The Journal of Biological Chemistry 273(49):32608-32613 1998.75Giuseppe Piedimonte, et al., "Association of Tyrosine Protein Kinase Activity With Mitochondria in Human Fibroblasts," Journal of Cellular Biochemistry 32:113-123 (1986).76GODIC, "New approaches to psoriasis treatment. A review." 2004. Acta Dermatoven APA, vol. 13, No. 2, pp. 50-57.77Goethals, I., et al. (2003) Eur. J. Nucl. Med. Mol. Imaging 30(2):325-328.78Gorczyca, W., et al., "Induction of DNA Slrand Breaks Associated with Apoptosis During Treatment of Leukemias," Leukemia 7(5):659-670 1993.79Gordon, C., et al.. "Chronic Therapy with Recombinant Tumor Necrosis Factor-or in Autoimmune NZB/NZW Fi Mice,"Clinical Immunology and Immunopatholoy—52:421-434 (1989).80Gordon, E.M., et al., Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic 52 Synthesis, Library Screening . . . Journal of Med. Chem. 37(10): (1994).81Grasberger, Bruce L., "Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells", J. Med. Chem., 48, (2005), 909-912.82Griffith, C.E., Br. J. Dermatol., Apr. 2001; 144(4):679-81.83Gupta et al., "Psychitripic drugs in dermatology . . . " Database:EMbase (AN:86111413), Journal of the American Academy of Dermatology, 1986, vol. 14, No. 4, pp. 633-645.84Hahn, B.H., et al.; "Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders . . . ," Arthritis and Rheumatism—18(2):145-152 (1975).85Hamann, L.G., et al., "Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase" Bioorganic & Medicinal Chemistry Ltrs. 14 pp. 1031-1034 (2004).86Hang, L., et al., "A Spontaneous Rheumatoid Arthritis-Like Disease in MR/1 Mice," J. Exp. Mod.—155:1690-1701 1982.87Herranz, R., "Cholesystokinin Antagonists: Pharmacological and Therapeutic Potential", Medicinal Research Reviews 23 (2003) 559-603.88Hirsch, et al., "PK11195, a Ligand of the Mitochondrial Benzodiazepine Receptor, Facilitates the Induction of Apoptosis and Reverses Bcl-2-Mediated Cytoprotection," Experimental Cell Research 241, 426-434 (1998).89Horowitz, R.E., et al., "Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus," Laboratory Investigation 21 (3): 199-206 1969.90Hulme, C. J. "Improved procedure for the solution phase preparation of 1,4-benzodiazepine-2,5-dione libraries . . . ", Org. Chem., 63,(1998), 8021-8023.91Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science, 246:1275-1281 [1989].92Iiangumaran, et al., "CD44 Selectively Associates with Active Src Family Protein Tyrosine Kinases Lck and Lyn in Glycosphingolipid-Rich . . . ", Blood, vol. 91, No. 10 (May 15, 1998), pp. 3901-3908.93International Preliminary Report on Patentability, PCT/US2006/041446, mailed May 8, 2008.94International Report on Patentability, PCT/US2006/000442 mailed Jul. 12, 2007.95International Search Report and Written Opinion dated Mar. 27, 2009, PCT/US2008/076021.96International Search Report and Written Opinion of PCT/US2008/057827 dated Oct. 6, 2008.97International Search Report and Written Opinion, PCT/US05/14463, mailed Dec. 4, 2006.98International Search Report and Written Opinion, PCT/US07/11422, mailed Nov. 15, 2007.99International Search Report and Written Opinion, PCT/US07/13576, mailed Nov. 23, 2007.100International Search Report and Written Opinion, PCT/US08/56231, mailed Jun. 24, 2008.101International Search Report and Written Opinion, PCT/US2006/00442, mailed May 12, 2006.102International Search Report and Written Opinion, PCT/US2008/082629, mailed Jun. 1, 2009.103International Search Report, International Patent Application No. PCT/US005/031942 dated Sep. 21, 2006.104International Search Report, International Patent Application No. PCT/US01/11599 dated Mar. 6, 2001.105International Search Report, International Patent Application No. PCT/US02/26171 dated Aug. 8, 2003.106International Search Report, International Patent Application No. PCT/US04/013455 dated Jan. 6, 2006.107International Search Report, International Patent Application No. PCT/US05/24060, dated Dec. 13, 2006.108International Search Report, PCT/US06/042753, mailed Apr. 19, 2007.109International Search Report, PCT/US06/41446, mailed Aug. 1, 2007.110International Search Report, PCT/US2006/042753, dated May 6, 2008.111IPER and ISR for PCT/us02/31942 mailed Feb. 2, 2007.112Itoh, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," Cell 66:233-243 (1991).113Ji Yang, et al., "Prevention of Apoptosis by BCL-2; Release of Cytochrome c from Mitochondria Blocked" Science vol. 275, No. 5303, pp. 1129-113221 (1997).114Johnson, et al., "Mechanistic Basis for Therapeutic Targeting of the Mitochondrial FF-ATPase", downloaded from http://pubs.acs.org on Dec. 5, 2008, ASC Chem. Biol. 1 (5), 304-308, Publication Date (WEB): Jun. 9, 2006.115Johnson, K.M., et al., Chemistry & Biology, 2005, 12:486-496.116Jones, The non-conalent interaction of pyrrolo[2, 1-c][benzodiazepines-5, 11-diones with DNA, Anti-Cancer Drug Design, 5:249-264 (1990).117Joshi, et al., "Oligomycin Sensitivey-conferring Protein (OSCP) of Mitochodrial ATP Synthase," The Journal of Biological Chemistry, Vol. 267, No. 18,m Issue of Jun. 25, pp. 12860-12867, 1992 .118Juaristi, Eusebio, et al., "Enantioselective Synthesis of α-Amino Acides from Chiral 1, 4-enzodiazepine-2, 5-diones Contianing the α-Phenethyl Group," Journal of Organic Chemistry, 1999, Mar. 26, vol. 64, No. 8, pp. 2914-2918.119Kamal, A., "Synthesis of DNA-interactive Pyrrolo[2,1-c][1,4] benzodiazepines by employing polymer-supported reagents . . . ," Synlett, 14,(2004), 2533-35.120Karle Jesper et al., "Diazepam protects against rat hippocampal neuronal cell death induced by antisense oligodeoxynucleotide to GABA-A receptor gamma-2 subunit" Brain Research, vol. 765, No. 1, 1997, pp. 21-29.121Keating, Thomas A., et al., "A Remarkable Two-Step Synthesis of Diverse 1, 4-Benzodiazepine-2, 5-diones Using the Ugi Four-Component Condensation," Journal of Organic Chemistry, 1996, vol. 61, No. 25, pp. 8935-8939.122Kerver et al, "In situ detection of spontaneous superoxide anion and singlet oxygen production by mitochondria in . . . ", Histochem. J., 29:229-237 [1997] (Abstract only).123Kim et al., "Synthesis of 3-substituted 1,4-benzodiazepin-2-ones," J. Braz. Chem. Soc. 9:375-379 (1998).124Kluge, et al., "Kinetics of Inactivation of the F1F0 ATPase of Propionigenium modestum by Dicyclohexylcarbodiimide in Relationship to H+ and Na+ Concentration: Probing the Binding Site for the Coupling Ions," Biochemistry 1993, 32, 10378-10386.125Kohler and Milstein, "Continuous cultures of fused cells . . . ", Nature, 256:495-497 [1975].126Koopman, W.J., et al., "The MRL-Ipr/Ipr Mouse. A Model for the Study of Rheumatoid Arthritis," Scan& J. Rheumatolo Suppl 75:284-o289 (1988).127Korsmeyer, S.J., "BcI-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," Blood 80(4):879-886 1992.128Kozbor, et al. ."The production of monoclonal antibodies from human lymphocytes", Immunol. Today, 4:72 [1983].129Kozbor, et al. •"The production of monoclonal antibodies from human lymphocytes", Immunol. Today, 4:72 [1983].130Krueger GC, et al., (1984), J. Am. Acad. Dermatol., 11:937-947.131Kyungjin, Kim, Steven K. Volkkan, and Jonathan A. Ellman, Synthesis of 3-Substituted 1,4-Benzodiazepin-2-ones, J. Braz. Chem. Soc. vol. 9(4), 375-379 (1998).132Lacapere, J.J., et al. (2003) Steroids 68(7-8):569-585.133Laupacis, et al., "Cyclosporin A: a powerful immunosuppressant", CMA Journal, May 1, 1982, vol. 126, pp. 1041-1046.134Lee, et al., J. Org. Chem. 1999, 64, 3060-3065.135Lee, Sunwoo, et al., "Improved Catalysts for the Palladium-Catalyzed Synthesis of Oxindoles by . . . ", J. Org. Chem. 2001, 66, pp. 3402-3415.136Levitzki, Alexander, "Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents," Pharmacol. Ther. vol. 82, Nos. 2-3, pp. 231-239 (1999).137Lewis et al., "Editors' view: Cancer pharmacotherapy: 21st century ‘magic bullets’ and changing paradigms", British Journal of Clinical Pharmacology, 2006, 62:1,pp. 1-4.138Lewis et al., "Editors' view: Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms", British Journal of Clinical Pharmacology, 2006, 62:1,pp. 1-4.139Liu, J.R., et al., "Bclox.. is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-induced Apoptosis," Gynecologic Oncology 70:398-403 (1998).140Liu, J.R., et al., "Bclox•. is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-induced Apoptosis," Gynecologic Oncology 70:398-403 (1998).141Los, M., et al., The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Immunity-10:629-639 (1999).142Lowe, "Systemic treatment of severe psoriasis," The New England Journal of Medicine, 324 (5), Feb. 7, 1991, pp. 333-334.143Lowman, et al., "Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen", J. Biol.Chem. 266:10982 [1991].144Luria,et al., "Tumor Viruses", General Viology 3rd edition,. 436-446 (1978)-Eds. John Wile & Sons, New York.145Luria,et al., "Tumor Viruses", General Viology 3rd edition,. 436-446 (1978)—Eds. John Wile & Sons, New York.146Mahrle, et al., Br. J. Bermatol. 1974, 91, 529-540.147Malgrange, B., et al., "I-Carbolines Induce Apoptotic Death of Cerebellar Granule Neurones in Cultures," NeuroReport 7(18):3041-3045 (1996).148Marc, Gasper, et al., "High Yield Phase Transfer N-Alkylation of Some Benzodiazepinese by Esters of ω-Halo Acids," Synthetic Communications, 1998, vol. 28, No. 7, pp. 1143-1157.149Marino, M., et al., "Prevention of Systemic Lupus Erythematosus in MRL/Ipr Mice by Administration of an Immunoglobulin . . . , " Nature Biotechnology -18:735-739 (2000).150McDonnell-349:254-256T J et al., Progression from Lymphoid Hyperplasia to High-Grade . . . Nature-349:254-256 (1991).151McDonnell—349:254-256T J et al., Progression from Lymphoid Hyperplasia to High-Grade . . . Nature—349:254-256 (1991).152Miccoli, et al., "Potentiation of Lonidamine and Diazepam . . . ", Journal of the National Cancer Institute, vol. 90, No. 18, pp. 1400-1406, Sep. 1998.153Miernik et al., "The antimitotic activities of some benzodiazepines", Experientia, 1986, 42, pp. 956-958.154Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis . . . , " Society for Neuroscience Abstracts-24(1-2):979 (1998).155Miller, K.A., et al., "Benzodiazepines Prevent Neuronal Death by Apoptosis & Necrosis . . . , " Society for Neuroscience Abstracts—24(1-2):979 (1998).156Mohiuddin, G., et al., "A Versatile Synthesis of 3H-1(H), 4(H)-Benzodiazepin-2,5-diones," Indian Journal of Chenmistry, 1985, vol. 24B, pp. 905-907.157Monks, A., et., Feasibility of High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines, Journal of the National Cancer Institute, 83:757-766 (1991).158Mui et al. Br. J. Dermatol. 1975, 92, 255-262.159Nadin, Alan, et al., "New Synthesis of 1,3-Dihydro-1,4-benzodiazepin-2(2H)-ones and 3-Amino-1,3-dihydro-1,4-benzodiazepin-2(2H)-ones: Pd-Catalyzed Cross-Coupling of Imidoyl Chlorides with Organoboronic Acids," J. Org. Chem., 2003, 68, pp. 2844-2852.160Nagata, S., "Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A 55 Lesson from the Mouse Model," J. Hum. Genet 43:2-8 (1998).161Nawrocka, et al., Arch. Pharm. (Weinheim) Jan. 2001, 334(1), 3-10.162Office Action Mailed Apr. 3, 2009, U.S. Appl. No. 11/176,719, filed Jul. 6, 2005.163Office Action Mailed Aug. 19, 2009, U.S. Appl. No. 11/176,719, filed, Jul. 6, 2005.164Office Action Mailed May 24, 2010, U.S. Appl. No. 11/176,719, filed Jul. 6, 2005.165Okuyama, H., et al., "Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice Bearing Ipr Gene," Clln. Ex p. ImmunoL 63:87-94 1986.166Okuyama, H., et al., "Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity . . . , " Int Arch. Allergy Appl. Immunol. 88:394-40 (1989).167Otto, M.W., et al. (2005) J. Clin. Psychiatry 66 Suppl. 2:34-38.168Ozols, R.F., "Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer," Seminars in Oncology 26(1) (Supp.2:84-89 (1999).169Paola Costantini et al., "Mitochondrion as Novel Target of Anticancer Chemotherapy", JNCI Journal of the National Cancer Institute 2000 92(13): 1042-1053; doi:10. 1093/jnci/92. 13. 1042. (2000).170Papadopoulo, V. (2003) Ann. Pharm. Fr. 61(1):30-50.171Parks, Daniel J. "1,4-benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction . . . " Bioorg Med Chem. Ltrs,. 15,(2005), 765-770.172 *Patani, George, et al , "Bioterrorism: A Rational Approach to Drug Design," Chem. Rev., vol. 96, pp. 3147-3176 (1996).173Paull, K.D., et al., "Display and analysis of patterns of differential activity of drugs against human tumor . . . ", J. Natl. Cancer Inst., 81:1088-1092 [1989] (Abstract only).174Pestell, K.E., et al., "Charactehsation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of . . . , " Int J. Cancer—77:913-918 (1998).175Prindull, "Apoptosis in the embryo and tumorigenesis" European Journal of Cancer, vol. 31, Issue 1 (1995) pp. 116-123.176Puodziunaite, B., et al., "Bromination of Aromatic Ring of Tetrahydro-1,5-Benzodiazepin-2-Ones", Chemistry of Heterocyclic Compounds, vol. 36, No. 6, 2000.177Raboisson, P. "Structure-based design, synthesis and biological evaluative of novel 1,4-diazepines as HDM2 antagonists," Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861.178Ramdas et al., "Benzodiazepine compounds as inhibitors of the Src protein tyrosine kinase . . . " Archives of Biochemistry and Biophysics 368 (1999) 394-400.179Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels," Br. J. Cancer 74(3) :380-?386 (1996).180Reddy, Pavan, et al., "Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis," J. Exp. Med., 2001, 194: 1433-1440.181Russell, J.H., et al., "Mature T Cells of Autoimmune Ipr/lpr Mice have a Defect in Antigen-Stimulated Suicide,"Proc. Nat. Acad. Sci. USA 90:4409-4413 (1993).182Sakata, K., et al., "Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad," Clinical Immunology and Immunopathology 87(1):1-7 (1998).183Sanchez, et al., "Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2" Proc Natl Acad Sci U S A (Jun. 6, 1995) 92(12) 5287-5291.184Sandstrom, P.A., et al., Autocrine Production of Extracellular Catalase Prevents Apoptosis.. Proc. Natl. Acad. Sci. USA-90:4708-4712 (1993).185Sato, et al., "CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor," seminars in Immunology, vol. 10, 1998, pp. 287-297.186Schlumpf, M., et al., "Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines," Toxic. In Vitro—8 (5):1061-1065(1994).187Schoemaker, H., et al., "Specific High-Affinity Binding Sites for [3H]Ro5—4864 in Rat Brain and Kidney," The J. of Pharm and Experimental Therapeutics—225(1)61-69 (1983).188Schwab, M., et al., "Amplified DNA with Limited Homology to myc Cellular Oncogene is Shared by Human Neuroblastoma Cell Lines and . . . ," Nature-305:245-248 (1983).189Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/mp-Ipr/lpr and MRUMp-++ Mice," The Journal of Immunology—1322:633-639 (1994—.190Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," Cell 67:879-886 (1991).191Shaughnessy, Kevin, H., et al., "Palladium-Catalyzed Inter- and Intramolecular . . . " J. Org. Chem. 1998, 63, pp. 6546-6553.192Sheppard, R.C., et al., "Acid-Labile Resin Linkage Agents for Use in Solid Phase Peptide Synthesis;" Int J. Peptide Protein Res. 20:451-454 (1982).193Smyth, W.F., et al. (1998) Electrophoresis 19(16-17):2870-2882.194Snyder, Jane R., et al, "Dissection of melanogenesis with small molecules identifies prohibition as a regulator", Chemistry & Biol. 12:477-484, 4(2005).195Solomko, et al., Chemistry of Heterocyclic Compounds, vol. 11, No. 11, Nov. 1975, pp. 1231-1248.196Stern, R.S. (1995), dERMATOL. cLIN. 13:717-722.197Stevens, S.Y., et al., "Non Nucleic Acid Inhibitors of Protein-DNA Interactions Identified Through Combinatorial Chemistry," J. Am. Chem.Soc.—118:10650-10651 (1996).198Sugimoto, T., et al., Determination of Cell Surface Membrane Antigens . . . JNCI-73: (1):51-57 (1984).199Swanson et al, "Ligand recognition by anti-DNA Autoantibodies," Biochemistry, 35:1624-1633 [1996] (Abstract only).200Swanson, P.C., et al., "Ligand Recognition by Murine Anti-DNA Autoantibodies," J. Clin. Invest 97(7):1748-1760 (1996).201Swanson, P.C.,et al., "High Resolution Ephope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," J. Immunology 71 152(5):2601-2612 (1994).202Takahashi, T., et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand;" Cell 76:969-976 (1994).203Tanimoto, Y., et al., Benzodiazepine Receptor Agonists Modulate Thymocyte Apoptosis Through Reduction of the Mitochondrial . . . Jpn. J. Pharmacol. 79:177-183 (1999).204Tarpley, et al., J. Chroni Diseases (1965), 18 (abstract only).205Taupin, V., et al., Endogenous Anxiogenic peptide, ODN-Diazepam-Binding Inhibitor, and Benzodiazepines.. Lymphokine and Cytokine Research 10(1):7-13 (1991).206Theoffopoulous, AN, et al., "Murine Models of Systemic Lupus Erythematosus," Advances in Immunology 37:269-390 (1985).207Thompson, C.B., "Apoptosis in the Pathogenesis and Treatment of Disease," Science 267:1456-1462 (1995).208Ursini et al., "Synthesis and SAR of New 5-Phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists", J. Med. Chem. 43 (2000) 3596-3613.209Varani, et al., (1994), J. Clin. Invest., 94:1747-1753.210Varani, J., et al. (2001), J. Invest. Dermatol., 117:1335-1341.211Varani, J., et al., "A Novel Benzodiazepine Selectively Inhibits Keratinocyte Proliferation . . . ", The Journal of Pharmacology and Experimental Therapeutics, 2005, vol. 313, No. 1, pp. 56-63.212Walser, et al., "Quinazolines and 1,4-benzodiazepines. LILX. Preparation of Pyrrolo[2,1-c]-1,4-benzodiazepin-2-ones", J. Org. Chem. 38:3502-3507 (1973).213Watanabe-Fukunaga, R., et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosia,"Nature 356:314-317 (1992).214White, E., "Life, Death, and the Pursuit of Apoptosis," Genes & Development 10:1-15 (1996).215Williams, D. et al, "Identification of compounds the bind mitochondrial F1F0 ATPase by screening a triazine library . . . " Chemistry & Biol. 11:1251-1259, 9(2004).216Wolvetang, et al., FEBS Letters (1994), 339, 40-44.217Written Opinion of the International Searching Authority, PCT/US06/21561, dated Aug. 17, 2007.218Wu, G.Y., et al., "Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journal of Biological Chemistry 262(10):4429-4432 (1987).219Wyllie, A.H., "The Genetic Regulation of Apoptosis," Current Opinion in Genetics & Development 5:97-104 (1995).220Yasuda, K., (2004) Nippon Rinsho. 62 Suppl. 12:360-363.221Yoshi, M., et al., (2005) Nippon Yakurigaku Zasshi 125(1):33-36.222Yoshii, M., et al. (1998) Nihon Shinkeo Seishin Yakurigaku Zasshi, 18(2):49-54.223Zamzami, N., et al., "Mitochondrial Control of Nuclear Apoptosis," J. Exp. Med. 183:1533-1544 1996.224Zoratti, M., et al., "The Mitochondrial Permeability Transition," Biochimica et Biophysica Acta 1241:139-176 (1995).* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8791104May 17, 2013Jul 29, 2014The Regents Of The University Of Michigan1,4-benzodiazepine-2,5-diones with therapeutic propertiesClassifications U.S. Classification514/183, 540/498, 540/610, 540/54, 540/504, 540/204International ClassificationA61K31/33, C07D487/00, C07D223/04, C07J71/00, C07D243/12, A01N43/00, C07D221/00Cooperative ClassificationA61K31/5513, C07D243/14European ClassificationA61K31/5513Legal EventsDateCodeEventDescriptionJan 25, 2007ASAssignmentOwner name: REGENTS OF THE UNIVERSITY OF MICHIGAN, THE,MICHIGAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GLICK, GARY D.;REEL/FRAME:018842/0247Effective date: 20070112Owner name: REGENTS OF THE UNIVERSITY OF MICHIGAN, THE, MICHIGFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GLICK, GARY D.;REEL/FRAME:018842/0247Effective date: 20070112Jul 3, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services